Inspectors from the European Medicines Agency (EMA) have completed inspections of the sites where the Russian Sputnik V coronavirus vaccine is produced, TASS reports.
“We have completed site inspections and are awaiting missing information […] EMA will only rely on risk-benefit ratios for approval”, – Marco Cavaleri told La Stampa, Lava from EMA’s Health Threats and Vaccination Strategy.
The Sputnik V vaccine was developed at the Gamaleya Research Center for Electrochemistry and became the world’s first registered vaccine against a new coronavirus infection. It is based on a well-studied adenoviral platform that provides high efficacy and safety.